As Europe’s cannabis industry edges closer to a transformative new era, the spotlight is increasingly falling on medicinal cannabis in clinical settings. With evolving regulations, rising demand for evidence-based treatments, and a renewed focus on patient outcomes, clinical settings are at the heart of the cannabis conversation in 2025.

Cannabis Europa has become a pivotal platform for shaping the future of Europe’s cannabis sector – bringing together policymakers, healthcare professionals, and business leaders to discuss the region’s unique and responsible path toward cannabis regulation and innovation.

Growing Role of Medicinal Cannabis in Clinical Settings

One of the key topics expected to dominate discussion is how medicinal cannabis in clinical settings is being integrated into care – from pain management and palliative treatment to its growing use in managing conditions such as epilepsy, multiple sclerosis, and chemotherapy-induced side effects.

This growing adoption demands not only scientific rigour and clinical excellence but also a robust understanding of the regulatory environment. Healthcare providers, researchers, and manufacturers must all work together to ensure safe and compliant use.

WBR’s Support for Medicinal Cannabis in Clinical Settings

At Woodley BioReg, we specialise in helping life science and healthcare innovators navigate this complex, highly regulated space. Whether you’re developing cannabinoid-based therapies or looking to enter the UK or European market, we can support every step of the regulatory journey – from classification and dossier preparation to engagement with regulatory bodies and product registration.

How WBR Can Support You:

  • GMP / GDP Certification: Our team has successfully completed MHRA GDP certification for multiple clients across the UK and EU

  • Regulatory Pathway Guidance: We help determine whether your product should be classified as a medicinal product, medical device, or food supplement

  • Clinical Development Support: From trial design to ethics submissions, ensuring compliance with local and international standards

  • Dossier and Documentation Preparation: Experience with MHRA, EMA, and other agency requirements for regulatory submissions

  • Market Access Strategy: Building roadmaps from development to launch, including pricing, reimbursement, and real-world evidence

  • Regulatory Intelligence and Updates: Tracking evolving requirements across jurisdictions to keep your project on the right path

Looking Ahead

As the European cannabis sector matures, and more clinical data emerges to support the therapeutic potential of cannabinoids, companies must approach medicinal cannabis in clinical settings with confidence, integrity, and clarity.

With Cannabis Europa 2025 around the corner, we’re actively working with clients across the sector to drive innovation, patient access, and regulatory excellence.

For additional background on cannabis policy, visit the European Monitoring Centre for Drugs and Drug Addiction.

If you’re looking to bring a medicinal cannabis product to market, or need support understanding how new regulations could affect your business, Woodley BioReg is here to help.

Back to News + Insights